William M Gallagher
Overview
Explore the profile of William M Gallagher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
7467
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burke C, Glynn T, Jahangir C, Murphy C, Buckley N, Tangney M, et al.
Expert Rev Mol Diagn
. 2025 Feb;
:1-12.
PMID: 39973615
Introduction: Standard clinical parameters like tumor size, age, lymph node status, and molecular markers are used to predict progression risk and treatment response. However, exploring additional markers that reflect underlying...
2.
Krzyzanowska A, Higgins D, Barron S, Loughman T, ONeill A, Sheehan K, et al.
BJUI Compass
. 2025 Jan;
6(1):e474.
PMID: 39877562
Objectives: This study aimed to clinically validate the six-gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods: MCRS was evaluated...
3.
Keogan A, Nguyen T, Bouzy P, Stone N, Jirstrom K, Rahman A, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):18.
PMID: 39825009
Predicting long-term recurrence of disease in breast cancer (BC) patients remains a significant challenge for patients with early stage disease who are at low to intermediate risk of relapse as...
4.
Azam H, Veale C, Zitzmann K, Marcone S, Gallagher W, Prencipe M
PLoS One
. 2024 Dec;
19(12):e0309491.
PMID: 39671399
Background: The Androgen Receptor (AR) pathway is crucial in driving the progression of prostate cancer (PCa) to an advanced state. Despite the introduction of second-generation AR antagonists, such as enzalutamide,...
5.
McCaffrey C, Jahangir C, Murphy C, Burke C, Gallagher W, Rahman A
Expert Rev Mol Diagn
. 2024 Apr;
24(5):363-377.
PMID: 38655907
Introduction: Histological images contain phenotypic information predictive of patient outcomes. Due to the heavy workload of pathologists, the time-consuming nature of quantitatively assessing histological features, and human eye limitations to...
6.
Connor K, Conroy E, White K, Shiels L, Keek S, Ibrahim A, et al.
Sci Rep
. 2024 Feb;
14(1):2720.
PMID: 38302657
Here, we establish a CT-radiomics based method for application in invasive, orthotopic rodent brain tumour models. Twenty four NOD/SCID mice were implanted with U87R-Luc2 GBM cells and longitudinally imaged via...
7.
Jahangir C, Page D, Broeckx G, Gonzalez C, Burke C, Murphy C, et al.
J Pathol
. 2024 Jan;
262(3):271-288.
PMID: 38230434
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in...
8.
Lawler M, Sullivan R, Abou-Alfa G, McCloskey K, Keatley D, Feighan J, et al.
J Cancer Policy
. 2023 Oct;
38:100448.
PMID: 37839622
2023 marks the 25th anniversary of the Good Friday Agreement, which led peace in Northern Ireland. As well as its impact on peace and reconciliation, the Good Friday Agreement has...
9.
OReilly E, Khalifa K, Cosgrave J, Azam H, Prencipe M, Simpson J, et al.
J Nat Prod
. 2023 Sep;
86(9):2151-2161.
PMID: 37703852
Prostate cancer is the fifth leading cause of cancer death in men, responsible for over 375,000 deaths in 2020. Novel therapeutic strategies are needed to improve outcomes. Cannabinoids, chemical components...
10.
Thagaard J, Broeckx G, Page D, Jahangir C, Verbandt S, Kos Z, et al.
J Pathol
. 2023 Aug;
260(5):498-513.
PMID: 37608772
The clinical significance of the tumor-immune interaction in breast cancer is now established, and tumor-infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple-negative (estrogen receptor,...